Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Rozovski U"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-4 z 4
    Tytuł:
    Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study.
    Autorzy:
    Shimony S; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
    Yeshurun M; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
    Wolach O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
    Ram R; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Institute of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
    Rozovski U; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
    Shargian L; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
    Zukerman T; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, and Rappaport Faculty of Medicine - Technion, Haifa, Israel.
    Amit O; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Institute of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
    Bar-On Y; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Institute of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
    Krayem B; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, and Rappaport Faculty of Medicine - Technion, Haifa, Israel.
    Avni B; Institute of Hematology, Hadassah Medical Center and Hebrew University Faculty of Medicine, Jerusalem, Israel.
    Peretz G; Department of Hematology and Bone Marrow Transplantation, Soroka Medical center and Faculty of Medicine, Beer Sheva, Israel.
    Raanani P; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
    Pasvolsky O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2021 Oct; Vol. 62 (10), pp. 2475-2481. Date of Electronic Publication: 2021 Apr 21.
    Typ publikacji:
    Journal Article; Multicenter Study; Observational Study
    MeSH Terms:
    Hematopoietic Stem Cell Transplantation*
    Leukemia, Myeloid, Acute*/drug therapy
    Humans ; Protein Kinase Inhibitors/adverse effects ; Sorafenib/therapeutic use ; Staurosporine/analogs & derivatives ; fms-Like Tyrosine Kinase 3/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Early detection of infectious complications during induction therapy for acute leukemia with serial C-reactive protein biomarker assessment.
    Autorzy:
    Shimony S; Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.
    Rozovski U; Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.
    Sudry N; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.
    Yeshurun M; Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.
    Yahav D; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.; Infectious Disease Unit, Beilinson Hospital, Rabin Medical Centre, Petah-Tikva, Israel.
    Raanani P; Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.
    Wolach O; Institute of Hematology, Davidoff Cancer Centre, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Ramat-Aviv, Israel.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2020 Nov; Vol. 61 (11), pp. 2708-2713. Date of Electronic Publication: 2020 Jun 24.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Febrile Neutropenia*
    Leukemia, Myeloid, Acute*/diagnosis
    Leukemia, Myeloid, Acute*/drug therapy
    Biomarkers ; C-Reactive Protein ; Humans ; Induction Chemotherapy/adverse effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    MYC protein expression is an important prognostic factor in acute myeloid leukemia.
    Autorzy:
    Ohanian M; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Rozovski U; b Department of Hematology , Davidoff Cancer Center at Rabin Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv , Israel.
    Kanagal-Shamanna R; c Department of Hematopathology , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Abruzzo LV; d Department of Pathology , Ohio State University , Columbus , OH , USA.
    Loghavi S; c Department of Hematopathology , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Kadia T; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Futreal A; e Department of Genomic Medicine , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Bhalla K; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Zuo Z; c Department of Hematopathology , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Huh YO; c Department of Hematopathology , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Post SM; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Ruvolo P; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Garcia-Manero G; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Andreeff M; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Kornblau S; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Borthakur G; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Hu P; f School of Health Professions , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Medeiros LJ; c Department of Hematopathology , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Takahashi K; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Hornbaker MJ; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Zhang J; e Department of Genomic Medicine , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Nogueras-González GM; g Department of Biostatistics , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Huang X; g Department of Biostatistics , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Verstovsek S; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Estrov Z; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Pierce S; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Ravandi F; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Kantarjian HM; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Bueso-Ramos CE; c Department of Hematopathology , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Cortes JE; a Department of Leukemia , The University of Texas at MD Anderson Cancer Center , Houston , TX , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2019 Jan; Vol. 60 (1), pp. 37-48. Date of Electronic Publication: 2018 May 09.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    Biomarkers, Tumor/*metabolism
    Bone Marrow/*pathology
    Leukemia, Myeloid, Acute/*mortality
    Neoplasm Recurrence, Local/*diagnosis
    Proto-Oncogene Proteins c-myc/*metabolism
    Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biopsy ; Chemoradiotherapy/methods ; Disease-Free Survival ; Feasibility Studies ; Female ; Follow-Up Studies ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/pathology ; Leukemia, Myeloid, Acute/therapy ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Remission Induction/methods ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia.
    Autorzy:
    Rozovski U; Department of Leukemia, The University of Texas M. D. Anderson Cancer Center , Houston, TX , USA.
    Ohanian M
    Ravandi F
    Garcia-Manero G
    Faderl S
    Pierce S
    Cortes J
    Estrov Z
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2015 May; Vol. 56 (5), pp. 1392-7. Date of Electronic Publication: 2014 Nov 03.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    Central Nervous System Neoplasms/*epidemiology
    Central Nervous System Neoplasms/*secondary
    Leukemia, Myeloid, Acute/*complications
    Leukemia, Myeloid, Acute/*epidemiology
    Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Central Nervous System Neoplasms/diagnosis ; Cytarabine/administration & dosage ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Odds Ratio ; Prognosis ; Risk Factors ; Survival Analysis ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-4 z 4

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies